MSD’s pneumococcal vaccine candidate shows promise in paediatric studies
21st May 2021
An investigational pneumococcal conjugate vaccine (PCV) candidate, developed by MSD, has achieved positive topline results in a Phase III paediatric study.
The vaccine candidate – V114 – is an investigational 15-valent PCV, consisting of pneumococcal polysaccharides from 15 serotypes, conjugated to a CRM197 carrier protein.
This includes serotypes 22F and 33F, commonly associated with invasive pneumococcal disease and are not contained in the pneumococcal conjugate currently licensed for use in children and adults.
Results from two trials of V114 in MSD’s Phase III paediatric clinical programme found that the investigational candidate met its primary immunogenicity and safety endpoints.
Moskva Punasel väljakul toimub tavapärane 9 mai paraad
err.ee - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from err.ee Daily Mail and Mail on Sunday newspapers.
Olomoucké novinky - Domácí - Kdo zaútočí první? Bude to Rusko nebo Ukrajina?
olomouckenovinky.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from olomouckenovinky.cz Daily Mail and Mail on Sunday newspapers.